Novartis entered a second partnership with Orionis Biosciences to advance induced proximity approaches described as “molecular glue” work. The companies cited a prior relationship that included a deal signed in March 2020 and said the new agreement targets multiple disease areas. Orionis focuses on induced proximity designs intended to bring therapeutic proteins or protein complexes into functional alignment, a strategy that can create selectivity through engineered interaction rather than classic active-site inhibition. The agreement adds another high-profile corporate bet for Novartis within the rapidly developing molecular glue category, where partnering is often used to diversify discovery risk and accelerate access to platform-specific chemistry and biology.